Not sure that was exactly Truth in Advertising but one never knows.
On the ABX front, lots haven't heard of Brilacidin.... like the U of MD lead researcher who is advancing their HDP-M, who said (via email): "I knew about Pokymedix but didn't realize Cellceutix had taken things over..."
Seems like Aprea and CTIX are close to neck and neck, though the former better backed. Hopefully we'll find that Big Rx partner to help expedite our pipeline as they Science continues to merit it.
EXCERPT For some years now, big drugmakers have been disappointed by the performance of their in-house labs, and have increasingly looked outside for small firms with promising ideas. Nils Behnke, a partner at Bain, says that over the period covered by its study, the best-performing drug companies got more than 70% of their revenues from products that were not developed in-house.
The smaller, younger drug firms being bought in such deals can often be better than the pharma giants at thinking up new ways to attack a disease. But they typically lack the expertise to organise clinical trials, deal with regulators and get a drug successfully to market. These are the strengths of the big pharma firms. So combining the two sets of skills makes sense.
Market Data 
Markets 
AI
